The treatment of acute myeloid leukemia (AML) has historically relied on cytotoxic
chemotherapy, but modern understanding of AML biology has paved the way for new …

Simple Summary Molecularly targeted therapy is now a standard treatment option for
patients with acute myeloid leukemia and IDH1/2 or FLT3 mutations. This review …

Simple Summary Acute myeloid leukemia (AML) is a dangerous cancer of the blood. In
recent years, a series of drugs was approved to specifically target misdirected processes in …

Highlights•Despite advances with IDH1/2, FLT3, and BCL-2 directed therapies, treatment
resistance and relapse remain frequent•Activating RAS mutations are associated with …

Simple Summary Acute myeloid leukemia (AML) is one of the most common types of
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …

The introduction of new targeted therapies to the treatment algorithm of acute myeloid
leukemia (AML) offers new opportunities, but also presents new challenges. Patients …

Recent advances in FLT3 and IDH targeted inhibition have improved response rates and
overall survival in patients with mutations affecting these respective proteins. Despite this …

Treatment of FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive
acute myeloid leukemia (AML) remains a challenge despite the development of novel FLT3 …

The advent of small molecule-based targeted therapy has improved the treatment of both
acute and chronic leukemias. Resistance to small molecule inhibitors has emerged as a …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …